NASDAQ · ARQT

Arcutis Biotherapeutics, Inc.

Smart money pulse

What insiders and funds are doing

Selling Insiders: as of Nov 12 Funds: as of Jun 30, 2026
−1000+100 −51
  • account_balance
    131 funds bought, 135 sold in the quarter ended Jun 30, 2026. 45 were new holders.
  • info
    2 real insider sales in 12 months. $170K in total, not counting planned sales.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

275 funds report owning ARQT, up from 271

Holdings as of Jun 30, 2026
New45
Added86
Held50
Trimmed94
Sold out41

Last quarter

Who bought and who sold

BlackRock, Inc.
+15%
Polar Capital Holdings PLC
+17%
State Street Corp
−8%
Vanguard Capital Management LLC
+2%
Jennison Associates LLC
−15%
Morgan Stanley
+6%
D. E. Shaw & Co., Inc.
+58%
Gilder Gagnon Howe & Co LLC
−69%

Change in shares held, biggest holdings first. Bars stop at ±100%.

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale
CEOCFOOther officersDirectorsDecJanFebMarAprMayJunJulAugSepOctNovStock grant · Oct 23 · 2,819 shPlanned sale (10b5-1) · Nov 2 · $38.8KOption exercise · Nov 4 · $146KPlanned sale (10b5-1) · Nov 4 · $1.37MOpen-market sale · Nov 2 · $170K
CEOCFOOther officersDirectorsJunJulAugSepOctNovStock grant · Oct 23 · 2,819 shPlanned sale (10b5-1) · Nov 2 · $38.8KOption exercise · Nov 4 · $146KPlanned sale (10b5-1) · Nov 4 · $1.37MOpen-market sale · Nov 2 · $170K

Last 6 months. A wider screen shows 12.

Showing 2 real trades. Hidden: 1 stock grant, 1 option exercise, 2 planned 10b5-1 sales. Those happen on a schedule and say little about what an insider thinks. Bigger dot means a bigger trade.

Real trades, newest first

Nov 2 Todd Watanabe See Remarks, Director Open-market sale $139K 4,377 sh at $31.86
Nov 2 Patrick Burnett EVP, Chief Medical Officer Open-market sale $30K 943 sh at $31.86

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Congress · last 12 months

Members of Congress who traded ARQT

All Congress trades
ARQT Arcutis Biotherapeutics, Inc. - Common stock Gilbert Cisneros CA-31 Purchase $1,001 – $15,000 Traded May 29, 2026 Reported Jun 8, 2026
ARQT Arcutis Biotherapeutics, Inc. - Common stock Gilbert Cisneros CA-31 Purchase $1,001 – $15,000 Traded Mar 3, 2026 Reported Apr 7, 2026
ARQT Arcutis Biotherapeutics, Inc. - Common stock Gilbert Cisneros CA-31 Partial sale $1,001 – $15,000 Traded Dec 11, 2025 Reported Jan 12, 2026

Amounts are the ranges members report, not exact amounts. Reports can come up to 45 days after the trade. From House and Senate STOCK Act reports. This is data, not advice.

Top holders

Biggest funds in ARQT

As of Jun 30, 2026
FundValueChange
Montanova Capital, LLC$326M+1%
BlackRock, Inc.$277M+15%
Frazier Life Sciences Management, L.P.$259MSame
Rubric Capital Management LP$217MSame
Polar Capital Holdings PLC$173M+17%

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate.

This is data, not investment advice. About StockToast